PUBLICATION

Global Business Reports

AUTHORS

Catherine Howe, Neha Premjee, Emma Johannes

United States Biopharmaceuticals 2018 Pre-Release

March 15, 2018

A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is recognized as the most prominent proponent of medical innovation around the world. As the industry moves from treatments towards cures and pipelines are developed around the notion of precision medicine, more and more life-changing therapies are entering the market. With an increasing amount of innovation stemming from small biotechnology companies and university spin-offs, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange. GBR’s 2018 U.S. Biopharmaceuticals Pre-release shines a spotlight on the Boston/Cambridge area and San Francisco Bay Area as top destinations for investment and biopharmaceutical activity.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Latin America Petrochemicals and Chemicals 2025 - Digital Interactive

Latin America’s petrochemical and chemical industries are undergoing rapid transformation in 2025. Across the region, companies are adapting to global oversupply, market volatility, and shifting trade flows by diversifying portfolios, investing in technology, and pursuing sustainability-led growth.

MORE PREVIOUSLY PUBLISHED

MACIG

"Kangankunde is set to become one of only a handful of rare earth mines built outside China."

SUBSCRIBE TO OUR NEWSLETTER